Royalty Pharma (STU:RPD) LT-Debt-to-Total-Asset : 0.36 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Royalty Pharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Royalty Pharma's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.36.

Royalty Pharma's long-term debt to total assets ratio declined from Dec. 2023 (0.38) to Dec. 2024 (0.36). It may suggest that Royalty Pharma is progressively becoming less dependent on debt to grow their business.

Royalty Pharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Royalty Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma LT-Debt-to-Total-Asset Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.36

0.41

0.36

0.38

0.36

Royalty Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.38	0.38	0.43	0.37	0.36

Royalty Pharma LT-Debt-to-Total-Asset Calculation

Royalty Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	6316.994	/	17402.693
	=	0.36

Royalty Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	6316.994	/	17402.693
	=	0.36

Royalty Pharma (STU:RPD) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Royalty Pharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (STU:RPD) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPRX:Mexico

Address

110 East 59th Street, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.